Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom by Lau, WC et al.
1 
 
 
 
 
Lau, WC; Murray, M; El-Turki, A; Saxena, S; Ladhani, S; Long, P; Sharland, M; (2015) Impact of 
pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine , 33 
(39) pp. 5072-5079. 10.1016/j.vaccine.2015.08.022. Downloaded from UCL Discovery: 
http://discovery.ucl.ac.uk/1470580 
 
ARTICLE 
Title: Impact of pneumococcal conjugate vaccines on childhood 
otitis media in the United Kingdom   
 
Wallis CY Lau1, Macey Murray2, Aisha El-Turki2,3, Sonia Saxena4, Shamez Ladhani5,7, Paul 
Long6 , Mike Sharland,7 Ian CK Wong,1,2 Yingfen Hsia7 
1Centre for Safe Medication Practice and Research, Department of Pharmacology and 
Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, 
China; 2Centre for Paediatric Pharmacy Research Research Department of Practice and 
Policy, UCL School of Pharmacy, United Kingdom; 3Department of Primary Care & Health 
Services, Brighton and Sussex Medical School, United Kingdom; 4School of Public Health 
Imperial College London and Chartfield Surgery, United Kingdom; 5Immunisation, Hepatitis 
and Blood Safety Department, Public Health England, United Kingdom; 6 Institute of 
Pharmaceutical Science &Department of Chemistry, King’s College London, United 
Kingdom;7Paediatric Infectious Disease Research Group, St George’s University of London, 
United Kingdom 
 
Corresponding author: 
Yingfen Hsia 
Paediatric Infectious Disease Research Group, St George’s University of London 
Jenner Wing, Level 2, Room 2.216F, Mail Point J2C, London SW17 0RE 
Tel: +44 (0)2087254851 
Email: yhsia@sgul.ac.uk 
 
Abstract  
Background: Studies have demonstrated a reduction for otitis media (OM) following the 
introduction of seven-valent pneumococcal conjugate vaccine (PCV7), but this has not been 
evaluated in the United Kingdom (UK). Moreover, there are limited data on any additional 
impact of PCV13 introduction in 2010.  
Methods: We conducted an observational cohort study to investigate the trends in OM 
incidence and associated antibiotic prescriptions in children aged <10 year-olds during 2002-
2012 using a national primary care database. Three time-periods were defined to estimate 
monthly incidence: pre-PCV7 (January 2002-August 2006), post-PCV7 (September 2007-
March 2010), and post-PCV13 (April 2011-December 2012).  
Results:  Overall annual OM incidence declined by 51.3% from 135.8 episodes/1000 
person-years in 2002 to 66.1 episodes/1000 person-years in 2012; antibiotic prescription 
rates for OM declined by 72.9% from 57.9 prescriptions/1000 person-years to 15.7 
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prescriptions/1000 person-years, respectively. PCV7 introduction was associated with 
significant decline in OM rates across all age-groups (21.8%; 95%CI, 20.2-23.4), including 
<2 year-olds (19.8%; 95%CI, 16.0%-23.5%); 2-4 year-olds (23.0%; 95%CI, 20.4%-25.4%) 
and 5-9 year-olds (20.2%; 95%CI, 17.6%-22.7%). There was an additional significant 
reduction in OM (18.5%; 95%CI, 16.7%-20.2%) and associated antibiotic prescribing 
(12.2%; 95%CI, 8.6%-15.6%) after the introduction of PCV13 across all age-groups. 
Conclusion: The introduction of PCV7 was associated with a 22% significant reductions in 
OM in children aged <10 year-olds with an additional 19% reductions after PCV13 
introduction. These declines are equivalent to 592,000 and 15,700 fewer consultations and 
OM-related hospitalizations, respectively, in England and Wales every year. Although the 
continuing decline in OM rates in our study suggests that further reduction may continue to 
occur, it is important to monitor long-term trends in all pneumococcal diseases, including OM 
and pneumonia, because of increasing replacement of non-vaccine pneumococcal 
serotypes in carriage and disease.  
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Introduction  
Otitis media (OM) is one of the most common infections during childhood causing middle ear 
inflammation and is associated with fever, ear pain or effusion. Despite being an acute self-
limiting condition that resolves spontaneously, it is among the leading causes for children to 
visit physician and is the most common reason for prescribing antibiotics to children with 
respiratory conditions [1]. The common bacterial pathogens to cause acute OM are 
Streptococcus pneumoniae, Haemophilus influenzae , and Moraxella catarrhalis either 
directly or as a complication of a viral upper respiratory tract infection [2]. Given the 
substantial economic and healthcare costs of pneumococcal disease and the emergence of 
penicillin- and multidrug-resistant pneumococcal strains [3,4], several countries have 
focused primarily on prevention rather than treatment by adding pneumococcal vaccination 
into their infant immunization schedules. In 2000, the 7-valent pneumococcal conjugate 
vaccine (PCV7) that protects against the seven most prevalent serotypes (4, 6B, 9V, 14, 
18C, 19F and 23F) was licensed in the United States (US) for use among infants and young 
children to prevent pneumococcal infections. In the United Kingdom (UK), PCV7 was 
introduced into the childhood immunization program in September 2006. Unlike other 
countries where the recommended 3-dose infant schedule, however, a 2-doses infant 
schedule at 2 and 4 months old with a booster after 12 months of age (2+1 schedule) was 
implemented, alongside a 12-month catch-up campaign for all children aged <2 years [5]. 
 
PCV7 introduction resulted in a rapid and sustained reduction in invasive pneumococcal 
disease (IPD) caused by the vaccine serotypes across all age-groups through direct and 
indirect (herd) protection [5]. Analysis of national Hospital Episode Statistics (HES) data also 
revealed 20% reduction in hospitalizations for pneumonia and empyema in England 
following PCV7 introduction [6]. The reduction in PCV7-type pneumococcal infections, 
however, was associated with an increase in non-vaccine serotypes in carriage and, 
consequently, in invasive disease, led to replacement of PCV7 in national immunization 
schedules with a 13-valent vaccine (PCV13) that provided protection against six additional 
serotypes (1, 3, 5, 6A, 7F and 19A) [7,8]. In the UK, PCV13 replaced PCV7 in April 2010 
without a catch-up for older children. In other developed countries in Europe and North 
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America, the success of PCV7 in reducing community acquired-pneumonia and OM has 
been demonstrated in a number of clinical trials and observational studies [9-17]. 
 
However, in the UK the impact of PCV7 to OM reduction and associated antibiotic 
prescription rates, where 2-dose infant schedule with a booster after 12 months of age was 
introduced, has not been assessed. Additionally, the additional benefit of PCV13 in further 
reducing the burden of OM and antibiotic use in children is uncertain. In this study, we used 
a national primary care database to assess trends in OM incidence and associated antibiotic 
prescriptions over an 11-year period encompassing the introduction of both PCV7 and 
PCV13 in the UK.   
 
Methods 
Study design 
We conducted a retrospective cohort study to estimate incidence of OM and associated 
antibiotic prescribing from a primary care electronic healthcare database in children between 
January 2002 and December 2012.  
 
Data source 
The IMS Health (previously known as Intercotinental Medical Statistics), is an international 
healthcare information company, collecting anonymized health information within the UK and 
across the world. The IMS Disease Analyzer (IMS-DA) (formally known as Mediplus) is a 
longitudinal electronic healthcare database managed by IMS, containing medical records 
from nationally representative general practices in the UK (England, Wales, Scotland, and 
North Ireland). There are around 125 general practices and more than 500 general 
practitioners (GPs) have agreed to contribute their patients’ medical data to IMS DA. GPs 
use the computer software to enter patient medical records in their daily clinical practice for 
patient management. Information held on the database includes patient demographics, 
diagnosis, clinical symptoms, and prescription details. The data are then electronically 
transmitted from GPs’ computer systems to IMS DA. The quality of data recording has been 
monitored by the IMS Health over time [18]. The  database contains approximately 2 million 
anonymous patient records and over 95 million prescriptions [19].  Diagnoses and clinical 
symptoms are coded using Read Clinical Terms, a hierarchical coding system [20,21]. The 
recorded Read codes are mapped to ICD-10 (International Statistical Classification Disease, 
10th Revision) terminology by IMS Health. Prescribed drugs are coded based on the 
Anatomical Therapeutic Chemical (ATC) classification issued by the European 
Pharmaceutical Market Research Association (EPhMAP) [22]. The database has shown to 
be of high quality and is widely used in pediatric pharmaco-epidemiological studies [23,24]. 
 
Identification of otitis media episode and associated antibiotic prescribing 
We included all children younger than 10 years, registered with a general practice for at least 
6 months during the study period. Children temporarily registered with a general practice 
were excluded to ensure that there was no duplication of the same patients being 
permanently registered at another participating general practice. We identified children with 
one or more OM diagnoses between January 2002 and December 2012 by searching the 
IMS-DA using pre-defined diagnostic codes (Supplement Table1). Due to the acute nature of 
OM, some children may have had multiple OM episodes which could lead to close 
monitoring by GPs, resulting in multiple GP surgery visits. A 14-day screening period was 
set from the initial OM episode and any subsequent OM record during the screening period 
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was classified as a follow-up visit for the same episode; OM diagnosis after this period was 
counted as a new episode [24]. A major advantage of IMS-DA data over other UK healthcare 
databases is that prescriptions are directly linked by the GP to a clinical diagnosis at the time 
of consultation [25]. Antibiotic groups were defined based on the therapeutic level 
Anatomical Therapeutic Chemical (ATC)-J010.  
 
Secular trends 
We estimated annual incidence of OM and associated antibiotic prescribing rates between 
2002 and 2012. Incidence was defined as the total number of OM episodes during the study 
period divided by the total person-years of the study population during the time period. We 
also calculated OM incidence with monthly time series data for the same period. The 
monthly incidence of OM was defined as total number of OM episodes during each month 
divided by the total person-months of the study population. The monthly incidence of 
antibiotic prescribing to OM treatment was also calculated for the study period. Age-specific 
incidence was calculated for the following age-groups: <2 year-olds, 2-4 year-olds, and 5-9 
year-olds. The 95% confidence intervals (CIs) were estimated using Poisson distribution. 
 
Interrupted time series analysis 
We used a segmented linear regression model of an interrupted time series (ITS) to 
compare the change in OM incidence and associated antibiotic prescribing rates before and 
after the introduction of PCV7 and PCV13. Because it is generally recommended to have at 
least 12 time points before and any intervention in ITS analysis [26], we also compared 
incidence change at monthly intervals before and after the introduction of both PCVs. The 
ITS analysis was divided into pre- and post-intervention segments and the difference 
between the two segments allowed individual assessment of the impact of each intervention 
[27]. Three time-periods were defined to estimate monthly incidence: pre-PCV7 (January 
2002-August 2006), post-PCV7 (September 2007-March 2010), and post-PCV13 (April 
2011-December 2012). A 12-month transition period after the introduction of each vaccine 
(September 2006-August 2007 for PCV7; April 2010-March 2011 for PCV13) was included in 
the model to allow for increasing vaccine uptake in the target age-groups. In September 
2006, the PCV7 was introduced into childhood immunization program. At the same time, a 
12-month catch-up campaign was initiated. The national coverage of PCV7 after the 12-
month transition period was 93.5% in children aged 12 month-old and 88.6% in children 
aged 24 month-old before the PCV13 replacement [28]. Similarly, the high vaccine uptake 
was reported after PCV13 introduction. The coverage after 12 months transition period of 
PCV13 introduction was 94.6% in children aged 12 month-old and 91.9% in children aged 24 
month-old [29]. There are strong seasonal fluctuations for seasonal variation where OM 
rates are significantly higher in the winter months than in the summer; this variation was 
adjusted by adding an indicator for specific calendar months in the model. The models were 
accounted for first-order autocorrelation as error terms of consecutive observations were 
often correlated. Residual analyses of the final models showed no evidence of 
autocorrelations. Data management and analyses were performed using Stata SE software 
version 11.0 (Stata Corp., College Station, TX, USA) and Statistical Analysis System (SAS) 
v9.3 (SAS Inc., United States).  
 
Ethical approval 
This study protocol was approved by the IMS Independent Scientific and Ethical Advisory 
Committee.  
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Results 
The study population comprised 567,275 children aged <10 year-olds contributing 2,297,996 
person-years between January 2002 and December 2012 from family practices contributing 
to the database. There were 240,419 OM episodes identified in 106,709 children and 41.1% 
(43,843/106,709) of children received an antibiotic for OM treatment over the 11-year period. 
The median age at 1st OM episode was 3.0 years (interquartile range [IQR]: 1-5 years) and 
approximately half of the episodes occurred in boys (52.2%; 55,672/106,709). There was 
approximately 46.6% (49,739/106,709) of children with more than one OM episode during 
study period.  
 
Incidence of otitis media  
During pre-PCV7 (2002-2005), the mean annual OM incidence was 133.3 episodes (95%CI, 
131.8-134.8) in <10 year-olds, with the highest incidence in <2 year-olds (204.4 
episodes/1000; 95% CI, 201.8-207.0), followed by 2-4 year-olds (180.6 episodes/1000; 95% 
CI, 179.1-182.2) and 5-9 year-olds (93.0 episodes/1000; 95% CI, 92.2-93.8). OM was 
strongly related to seasonality, with peak rates observed in winter months compared to the 
other months. The annual incidence of OM in <10 year-olds declined by 51.3% from 135.8 
episodes/1000 person-years (95% CI, 134.4-137.3) in 2002 to 66.1 episodes/1000 person-
years (95% CI, 64.9- 67.4) in 2012. 
 
Following a transition period of 12 months after PCV7 introduction (September 2006 to 
August 2007), there was a 21.8% (95% CI, 20.2-23.4%) decline in the monthly incidence of 
OM in children aged <10 years (Figure 1A). This decline was significant in <2 year-olds 
(19.8%; 95% CI, 16.0-23.5%), 2-4 year-olds (23.0%; 95% CI, 20.4-25.4%) and 5-9 year-olds 
(20.2%; 95% CI, 17.6-22.7%) (Figure 2). After PCV13 introduction, there was an additional 
18.5% (95% CI, 16.7-20.2%) decline in monthly OM incidence overall, with significant 
declines observed among <2 year-olds (6.6%; 95%CI, 1.9-11.0%), 2-4 year-olds (13.0%; 
95% CI, 10.1-15.9%) and 5-9 year-olds (20.0%; 95% CI, 17.3-22.6%) (Figure 2).  
 
Antibiotic prescription rates for otitis media treatment  
The antibiotics prescribed for OM were consistent year-on-year over the whole study period 
(Supplement Figure1). Amoxicillin was the most commonly prescribed antibiotic, accounting 
for 78.1-82.3% of OM-associated prescriptions annually, followed by erythromycin (6.8-
8.7%), co-amoxiclav (3.1-4.7%), penicillin V (1.5-2.3%), clarithromycin (0.5-2.2%) and others 
(3.0-6.8%). A seasonal variation was also observed for antibiotic prescription rates, with 
higher rates in winter months compared with other months (Figure 3). Overall, antibiotic 
prescription rates fell by 72.9%, from 57.9 prescriptions/1000 person-years (95% CI, 56.9-
58.9) in 2002 to 15.7 prescriptions/1000 person-years (95% CI, 15.1-16.3) in 2012.  
 
Antibiotic prescribing rates for OM were already declining before the introduction of 
pneumococcal conjugate vaccination (Figure 1B). After PCV7introduction, however, there 
was an additional 18.9% (95% CI, 16.0-21.7%) monthly reduction in antibiotic, prescription 
rates overall and for <2 year-olds (18.5%; 95%CI, 11.7-24.7%), 2-4 year-olds (17.5%; 
95%CI, 12.9-21.9%), and 5-9 year-olds (21.8%; 95%CI, 17.2-26.2%) (Figure 3). 
Replacement of PCV7 with PCV13 was associated with a further 12.2% (95%CI, 8.6-15.6%) 
monthly reduction in antibiotic prescription rates overall, but this reduction was only 
significant for 5-9 year-olds (18.6%; 95%CI, 13.1-23.8%) (Figure 3). 
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Discussion 
The introduction of pneumococcal conjugate vaccine into the UK childhood immunization 
program was associated with a significant decline in the incidence of OM and associated 
antibiotic prescribing in children younger than 10 years of age. As is typical of OM, children 
aged less than <2 years had the highest rates with a characteristic winter peak. Although 
PCV7 was targeted at younger children, the similar significant declines in OM incidence 
were observed across all age groups studied. Replacement of PCV7 with PCV13 in April 
2010 was associated further declines in OM incidence and associated antibiotic prescription 
rates. 
 
Older age children may benefit from the indirect impact of the program, as has been 
reported for invasive pneumococcal disease and hospitalizations for bacterial pneumonia 
and empyema in England and Wales.5,6 Since conjugate vaccines also prevent carriage, 
targeting the initial PCV7 program to include age-group with the highest pneumococcal 
carriage rates (<2 year-olds) resulted in more rapid indirect (herd) protection through 
reduced transmission of pneumococcal vaccine serotypes to unvaccinated and older 
children and adults. Since indirect protection lags behind direct protection, the continuing 
decline in OM incidence among 2-4 and 5-9 year-olds even after PCV13 introduction is likely 
due to a combination of the vaccinated cohorts getting older and the indirect protection 
offered to the older, unvaccinated age groups. 
 
At a population level, the 21.8% decline in OM incidence among <10 year-olds after PCV7 
introduction is equivalent to 356,000 fewer GP consultations and 9,400 fewer 
hospitalizations annually in England and Wales [30]. Replacement with PCV13 resulted in a 
further 18.5% decline in OM incidence in this age group, equivalent to 236,000 fewer GP 
consultations and 6,300 hospitalizations annually [30], resulting in large cost savings to the 
National Health Service in addition to the benefits achieved through prevention of IPD, 
bacterial pneumonia and empyema.  
 
A major consequence of the decline in the incidence of OM is the associated reduction in 
antibiotic prescription rates for OM. The antibiotics prescribed for children with otitis media 
are in accordance with treatment recommendations in the British National Formulary for 
Children (BNFC), with amoxicillin being the predominant antibiotic of choice [31].  The 
decline in antibiotic prescription rates for OM prior to PCV introduction is likely to have been 
driven by national campaigns to reduce antibiotic prescriptions for self-limiting, viral 
infections in children [32]. On the background of this decline, however, we observed further 
reductions in antibiotic prescription rates for OM following the introduction of PCV7 initially 
but also after replacement with PCV13. This is an important finding, given the global 
concerns regarding inappropriate antibiotic use and increasing antibiotic resistance rates.  
 
Findings in relation to previous studies 
The reduction of OM incidence in our study is similar to clinical trials and observational 
studies in other countries evaluating the effect of PCV7 in preventing childhood OM. A 
recent systematic review reported the efficacy of PCV7 against all-cause acute OM episodes 
to be 0-9% in randomized controlled trials but 17-23% in non-randomized observational 
studies, consistent with our findings [33]. We have additionally identified a further decline of 
a similar magnitude within two years of PCV13 introduction.  This is consistent with a recent 
US study using a health insurance claims database, there was a significant reduction in 
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primary care visits for OM and recurrent OM following PCV13 introduction, mainly in <2 
year-olds [34]. In the US, PCV7 introduction was associated with a 41% reduction in 
antibiotic prescriptions for OM in children aged <2 year-olds [17]. In France and the 
Netherlands, too, antibiotics prescriptions for OM fell significantly among 6-month to 2 year-
olds and 1-9 year-olds, respectively, after PCV7 introduction [35,36].  This is the first study to 
demonstrate further reductions in antibiotic prescription rates for OM after PCV13 
introduction.  
 
Strength & limitations 
Pneumococcal surveillance in England and Wales is restricted to laboratory-confirmed, 
invasive cases. This is the first UK study to investigate the impact of both PCV7 and PCV13 
on OM incidence and antibiotic use in a community setting. The strength of our study is its 
size, generalizability and representative coverage of patients attending GP surgeries across 
the UK (England, Scotland, Wales, and Northern Ireland). An important limitation of our 
study, however, is that we do not have pneumococcal serotype data and culture results for 
OM cases. The routine microbiology cultures are rarely taken from patients presenting to 
primary care with otitis media. This is a general limitation in UK primary care database. As 
the laboratory data and culture results are not available in the IMS DA, we were unable to 
investigate whether the frequency of Streptococcus pneumonia isolation changed in our 
study. In addition, since tympanocentesis is not performed for OM diagnosis GP clinical 
practice in the UK, there are no data available to assess the contribution of Streptococcus 
pneumonia to OM in different age groups or changes in serotype distribution following PCV 
introduction. OM is, therefore, invariably diagnosed clinically and is, therefore, subjective to 
the attending clinician. While this may have an effect on overall diagnosis rates for OM, it is 
unlikely to affect trends over time. Secondly, this is an ecological study to evaluate the 
impact of PCV on OM rates and we cannot directly attribute the observed reductions to PCV 
introduction. However, there were two statistical significant reductions on OM incidence 
when ITS was performed after the PCV interventions. In addition, we did not identify any 
systematic changes in diagnostic or administrative practices that might otherwise explain the 
reduction in OM incidence or associated antibiotic prescription rates following PCV7 
introduction or replacement with PCV13. Thirdly, the patients’ vaccination histories are not 
completely recorded in primary care database. In UK, the vaccination status is recorded in 
any of following medical records: 1) patient-held record or Personal Child Health Record for 
children (e.g. the Red Book); 2) patient’s GP record or other patient record; 3) Child Health 
Information System; 4) practice computer system [37]. The National Institute for Health and 
Care Excellence (NICE) guidance stated that vaccination status of children and young 
people should be checked at every appropriate opportunity [38]. As we cannot access to 
individual child’s health records in all aforementioned medical records, we were unable to 
accurately to ascertain immunization status in our study subjects. Fourthly, several 
predisposing risk factors to otitis media have been reported such as age, socioeconomic 
index, breastfeeding, smokers in the household, attending day care [39,40]. However, most 
of this information is not captured in the IMS DA so we cannot investigate whether some 
children have risk factors predisposing to otitis media in our study. Fifthly, otitis media is a 
self-limiting acute condition and it sometimes spontaneously resolves without the need for 
antibiotic treatment. We were unable to obtain data on those children who have OM but 
didn’t visit GP for antibiotic treatment in the community. Finally, as with all studies analyzing 
large administrative databases, there is potential for misclassification bias when using 
diagnostic codes to define OM. Clinicians may also prefer certain diagnostic codes over 
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others to support their clinical decision to prescribe or not prescribe antibiotics to individual 
patients. Although we did not conduct a validation study to verify diagnostic codes for OM, 
the codes that we used are similar to previous studies using the Read code system [41]. 
However, although code choice for analysis could potentially influence absolute counts and, 
possibly, age distribution of cases, such biases are unlikely to affect trends over time and 
therefore, the reduction in OM cases and antibiotic prescription rates are most likely to be 
attributable to PCV introduction. 
 
Conclusion 
The introduction of PCV7 was associated with a significant reduction in primary care 
consultations for OM and antibiotic prescribing rates, with a similar additional decline within 
two years of PCV7 replacement with PCV13. These reductions were observed not only in 
vaccine-eligible children but also among older children because of indirect protection and it 
is likely that older age groups not included in our study will also have benefitted from this 
indirect protection. Although the continuing decline in OM rates during 2012 suggests that 
further reductions may continue to occur, it will be important to monitor long-term trends in all 
clinical manifestations of pneumococcal disease, including OM and pneumonia, because of 
increasing replacement of non-vaccine pneumococcal serotypes in carriage and disease 
[5,42] 
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Figure 1A Interrupted time series analysis of monthly incidence of otitis media in children 
<10 year-olds, 2002-2012 
 
Figure 1B Interrupted time series analysis of monthly antibiotic prescribing rates for otitis 
media treatment in children <10 year-olds, 2002-2012 
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Figure 2 Interrupted time series analysis of monthly incidence of otitis media by age groups, 
2002-2012 
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*Indicates significant reduction (P<0.05). The orange shades represents the transition period for 
PCV7 (September 2006-August 2007) and PCV13 (April 2010-March 2011).  
Figure 3 Interrupted time series analysis of monthly antibiotic prescription rate for otitis 
media by age groups, 2002-2012 
  
 
 
*Indicates significant reduction (P<0.05). The orange shades represents the transition period for 
PCV7 (September 2006-August 2007) and PCV13 (April 2010-March 2011).  
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TABLE1 Otitis Media diagnostic codes in IMS Disease Analyze, 2002-2012 
FIGURE 1The most commonly prescribed antibiotics for otitis media treatment in children < 
10 year-olds 
 
SUPPLEMENT TABLE1 Otitis Media diagnostic codes in IMS Disease Analyze, 2002-
2012 
 
Read code Description Total episodes Percentage 
(%) 
F51.. Nonsupp otitis media + eustach 71,594 29.79 
F510. Acute non supp otitis media 49,897 20.75 
F52.. Suppurative otitis media 48,041 19.98 
F520. Acute suppurative otitis media 17,377 7.22 
F52z. Otitis media NOS 14,557 6.05 
F512. Chron ot med with eff-mucoid 11,458 4.77 
.F621 Acute nonsupp. otitis media 6,010 2.49 
F527. Acute right otitis media 3,938 1.64 
F526. Acute left otitis media 3,255 1.35 
.F62. Nonsuppurative otitis media 3,061 1.27 
F528. Acute bilateral otitis media 2,009 0.84 
.F625 Otitis media NOS 1,861 0.77 
.F631 Acute suppurative otitis media 1,07 0.50 
.F63. Suppurative otitis media 927 0.39 
F511. Chron ot media with eff-serous 752 0.31 
F523. Chronic supp.otitis media NOS 565 0.24 
F524. Purulent otitis media NOS 503 0.21 
.F623 Chronic mucoid otitis media 432 0.18 
F510z Acute nonsup.otitis media NOS 425 0.18 
F5100 Acute otit media with effusion 387 0.16 
F518. Chron ot med with eff-unspec 334 0.14 
F514. Nonsupp. otitis media unspec. 211 0.09 
F5101 Acute serous otitis media 210 0.09 
F5200 Acute supp.otit.media-drum OK 192 0.08 
F5201 Acute supp.otit.med.+drum rupt 162 0.07 
F5141 Serous otitis media NOS 147 0.06 
F5102 Acute mucoid otitis media 122 0.05 
F521. Chron supp ot med-tubotympanic 107 0.04 
F5142 Catarrhal otitis media NOS 96 0.04 
F513. Chron ot med with eff-other 87 0.04 
F512z Chronic mucoid otitis med. NOS 85 0.04 
F520z Acute supp. otitis media NOS 77 0.03 
A552. Postmeasles otitis media 72 0.03 
.F633 Chronic purulent otitis media 55 0.02 
F5240 Bilateral supp otitis media 48 0.02 
16 
 
.F622 Chronic serous otitis media 46 0.02 
.F63Z Purulent otitis media NOS 33 0.01 
F5112 Bilateral chron serous otitis 24 0.01 
F511z Chronic serous otit.media NOS 14 0.006 
F514z Nonsuppurat. otitis media NOS 13 0.005 
F522. Chron supp ot med-atticoantral 13 0.005 
F5143 Mucoid otitis media NOS 7 0.003 
F5131 Chron ot med with eff-purulent 4 0.002 
F5103 Acute sanguinous otitis media 2 0.001 
F5105 Acute allerg.mucoid otit.media 1 0.0004 
F5121 Mucosanguinous chr.otit.media 1 0.0004 
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